Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

7.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.9K
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
Drug Nomenclature01:17

Drug Nomenclature

1.8K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.8K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

6.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.3K
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

2.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.0K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

726
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
726

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SARS-CoV-2 Spike Protein's Structural Dynamics Affect the Activity of the Bebtelovimab Antibody.

Journal of chemical information and modeling·2026
Same author

Comparative Study of Molecular Descriptors and AI-Based Embeddings for Toxicity Prediction.

Chemical research in toxicology·2025
Same author

AI-Driven Integration of Transcriptomics, Quantum Mechanics, and Physiology for Predicting Drug-Induced Liver Injury in Data-Limited Scenarios.

Chemical research in toxicology·2025
Same author

DICTrank Is a Reliable Dataset for Cardiotoxicity Prediction Using Machine Learning Methods.

Chemical research in toxicology·2025
Same author

Leveraging FDA Labeling Documents and Large Language Model to Enhance Annotation, Profiling, and Classification of Drug Adverse Events with AskFDALabel.

Drug safety·2025
Same author

Enhancing Bias Assessment for Complex Term Groups in Language Embedding Models: Quantitative Comparison of Methods.

JMIR medical informatics·2024

Related Experiment Video

Updated: Jul 6, 2025

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness
03:14

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness

Published on: December 6, 2024

588

RxBERT: Enhancing drug labeling text mining and analysis with AI language modeling.

Leihong Wu1, Magnus Gray1, Oanh Dang2

  • 1Division of Bioinformatics and Biostatistics, FDA National Center for Toxicological Research, Jefferson, AR 72079, USA.

Experimental Biology and Medicine (Maywood, N.J.)
|January 3, 2024
PubMed
Summary

Researchers developed RxBERT, a specialized AI model for analyzing US drug labeling documents. This advanced natural language processing tool enhances drug safety reviews and regulatory decision-making by improving information extraction from complex texts.

Keywords:
Artificial intelligenceBERTdrug labelinglanguage modelnatural language processingpharmacovigilance

More Related Videos

Cloud-Based Phrase Mining and Analysis of User-Defined Phrase-Category Association in Biomedical Publications
09:20

Cloud-Based Phrase Mining and Analysis of User-Defined Phrase-Category Association in Biomedical Publications

Published on: February 23, 2019

8.7K
Visualizing Lignification Dynamics in Plants with Click Chemistry: Dual Labeling is BLISS!
10:40

Visualizing Lignification Dynamics in Plants with Click Chemistry: Dual Labeling is BLISS!

Published on: January 26, 2018

12.0K

Related Experiment Videos

Last Updated: Jul 6, 2025

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness
03:14

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness

Published on: December 6, 2024

588
Cloud-Based Phrase Mining and Analysis of User-Defined Phrase-Category Association in Biomedical Publications
09:20

Cloud-Based Phrase Mining and Analysis of User-Defined Phrase-Category Association in Biomedical Publications

Published on: February 23, 2019

8.7K
Visualizing Lignification Dynamics in Plants with Click Chemistry: Dual Labeling is BLISS!
10:40

Visualizing Lignification Dynamics in Plants with Click Chemistry: Dual Labeling is BLISS!

Published on: January 26, 2018

12.0K

Area of Science:

  • Computational linguistics
  • Regulatory science
  • Artificial intelligence in medicine

Background:

  • US drug labeling documents are vital for assessing drug efficacy and safety but pose challenges for traditional text mining due to their volume and free-text nature.
  • Advances in artificial intelligence (AI) and natural language processing (NLP) offer new methods for extracting critical information from these complex regulatory documents.
  • Existing NLP models may not be optimally tuned for the specific nuances and structure of FDA drug labeling data.

Purpose of the Study:

  • To develop and evaluate RxBERT, a transformer-based NLP model specifically pre-trained on FDA human prescription drug labeling documents.
  • To enhance the processing and utilization of drug labeling information for both research and regulatory review purposes.
  • To demonstrate the potential of customized large language models (LLMs) for sensitive regulatory document analysis.

Main Methods:

  • Developed RxBERT, a Bidirectional Encoder Representations from Transformers (BERT) model, by further pre-training BioBERT on FDA human prescription drug labeling documents.
  • Evaluated RxBERT on multiple regulatory datasets, including the NIST TAC dataset, the FDA ADE Eval dataset, and a US Drug Labeling dataset for text classification.
  • Compared RxBERT's performance against established NLP models like BERT and BioBERT.

Main Results:

  • RxBERT achieved competitive or superior performance compared to other NLP approaches.
  • Achieved 86.5 F1-scores on both the NIST TAC and FDA ADE Eval classification tasks.
  • Reached a prediction accuracy of 87% on the US Drug Labeling dataset for classifying texts into labeling sections.

Conclusions:

  • RxBERT, a transformer model tailored for drug labeling, demonstrates superior performance over the original BERT model.
  • RxBERT shows significant potential to aid researchers and FDA reviewers in processing drug labeling information, thereby advancing drug effectiveness and public health safety.
  • The study validates a pathway for creating customized LLMs for specialized, sensitive regulatory data.